INCY vs INSM
Incyte and Insmed Incorporated, both Healthcare
Insmed Incorporated is the larger company at $21B against $20B. Over the past year INCY returned +65% against +14% for INSM. Ryufin's sector-relative Smart Score puts INCY ahead, 10/10 against 2/10.
| Figure | INCY | INSM |
|---|---|---|
| Last close | $128 | $124 |
| Market cap | $20B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.1 | n/a |
| 1-year return | +65% | +14% |
| 5-year return | +66% | +415% |
| Ryufin Smart Scoresector-relative, 1–10 | 10/10 | 2/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.